GlassScriptPhysician profile
Arun Nagarajan
NPI 1801850268
$8,687.78
in general payments reported to CMS, 2019-2025
22 companies · $5,598 in 2025
The $5,598 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,495 · 2022: $207 · 2023: $172 · 2024: $217 · 2025: $5,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,825 · Travel and Lodging: $1,341 · Food and Beverage: $1,071 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,825.00 |
| Travel and Lodging | $1,341.02 |
| Food and Beverage | $1,070.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $4,331.32 | 2025 | Cabometyx |
| Lilly USA, LLC | $2,300.00 | 2021 | |
| Roche Sequencing Solutions, INC. | $750.00 | 2025 | |
| Taiho Oncology, INC. | $201.66 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $165.38 | 2021-2023 | |
| Caris Mpi, INC. | $153.22 | 2025 | Mi Cancer Seek |
| Janssen Biotech, INC. | $130.61 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $118.74 | 2021-2022 | |
| Glaxosmithkline, LLC. | $108.03 | 2024-2025 | Zejula, Jemperli |
| Abbvie INC. | $94.48 | 2025 | |
| Pfizer INC. | $62.33 | 2022-2025 | |
| Astellas Pharma US INC | $57.64 | 2022-2025 | Vyloy |
| Daiichi Sankyo INC. | $48.84 | 2024-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $40.50 | 2025 | Reblozyl |
| Genentech USA, INC. | $31.29 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $22.85 | 2023 | Vonjo |
| Pharmacyclics LLC, An Abbvie Company | $20.83 | 2023 | Epkinly, Imbruvica |
| Merck Sharp & Dohme LLC | $19.77 | 2025 | Welireg, Keytruda |
| Tersera Therapeutics LLC | $17.29 | 2023 | Zoladex |
| Biogen, INC. | $13.00 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Nagarajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.